Compare NUCL & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | CERS |
|---|---|---|
| Founded | 2023 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | EDP Services |
| Sector | Basic Materials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.6M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | NUCL | CERS |
|---|---|---|
| Price | $8.97 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 330.3K | ★ 1.4M |
| Earning Date | 05-22-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $4.63 | $1.15 |
| 52 Week High | $9.00 | $2.96 |
| Indicator | NUCL | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 70.27 | 57.58 |
| Support Level | $6.86 | $1.93 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.81 | 0.09 |
| MACD | 0.21 | 0.04 |
| Stochastic Oscillator | 92.71 | 100.00 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds the rights to the mineable, measured and indicated uranium deposit in the United States, referred to as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated 37.73 million pounds of near-surface uranium and the adjacent Cordex Zone Eagle's SMR technology. Eagle's mission is to supply uranium to the growing nuclear energy industry and play a role in the global transition to clean, reliable, and affordable energy.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.